
Pharmaceutical Inputs from Germany: NAM Calls on the USTR to Avoid Broad Tariffs
The National Association of Manufacturers (NAM) called on the United States to avoid imposing broad tariffs on pharmaceutical inputs from Germany. The NAM argued that

The National Association of Manufacturers (NAM) called on the United States to avoid imposing broad tariffs on pharmaceutical inputs from Germany. The NAM argued that

The relocation of supply chains is creating opportunities for the pharmaceutical industry in the United States and Mexico. The pharmaceutical and drug manufacturing industry contributes

In general, there are four main cancer treatment modalities: surgery, radiation therapy, chemotherapy and targeted therapies (in which drugs target specific molecules in the tumor

The pharmaceutical company Novartis will invest 50 million dollars in clinical research in Mexico in the next triennium. All drug candidates undergo proof-of-concept trials to

Tagrisso ranked # 1 among AstraZeneca’s top medicines by the amount of its sales in 2020. Sales of this drug totaled $ 4.328 million last

The National Association of Manufacturers (NAM) called on the United States to avoid imposing broad tariffs on pharmaceutical inputs from Germany. The NAM argued that

The relocation of supply chains is creating opportunities for the pharmaceutical industry in the United States and Mexico. The pharmaceutical and drug manufacturing industry contributes

In general, there are four main cancer treatment modalities: surgery, radiation therapy, chemotherapy and targeted therapies (in which drugs target specific molecules in the tumor

The pharmaceutical company Novartis will invest 50 million dollars in clinical research in Mexico in the next triennium. All drug candidates undergo proof-of-concept trials to

Tagrisso ranked # 1 among AstraZeneca’s top medicines by the amount of its sales in 2020. Sales of this drug totaled $ 4.328 million last